Published in Lancet Infect Dis on March 01, 2011
TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol (2014) 1.21
Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950-1963). Virchows Arch (2014) 0.77
IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. PLoS One (2016) 0.75
The tinea capitis campaign in Serbia in the 1950s. Lancet Infect Dis (2010) 1.57
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.52
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
Carcinoma of the thyroid with ewing family tumor elements and favorable prognosis: report of a second case. Int J Surg Pathol (2013) 1.46
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid (2007) 1.41
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch (2001) 1.30
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
Oncocytic lesions of the thyroid, kidney, salivary glands, adrenal cortex, and parathyroid glands. Int J Surg Pathol (2014) 1.10
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.08
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res (2010) 1.08
Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest (2002) 1.05
Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. Sao Paulo Med J (2012) 1.04
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol (2005) 1.04
Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch (2010) 1.01
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol (2010) 1.01
Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Mod Pathol (2004) 1.01
High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab (2007) 1.01
Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am (2008) 1.00
Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol (2005) 1.00
p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Mod Pathol (2003) 0.99
Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch (2001) 0.98
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell (2008) 0.95
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets (2012) 0.93
Patterns of beta-catenin expression in gastric carcinoma: clinicopathological relevance and mutation analysis. Int J Surg Pathol (2003) 0.93
The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer (2012) 0.92
Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol (2002) 0.92
Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol (2007) 0.92
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol (2006) 0.91
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Am J Clin Pathol (2009) 0.91
A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology (2009) 0.91
Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab (2003) 0.90
Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch (2005) 0.90
BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion? Hum Pathol (2009) 0.89
Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. Biochim Biophys Acta (2011) 0.89
Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. Genes Chromosomes Cancer (2012) 0.88
Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family. Thyroid (2004) 0.88
A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Fam Cancer (2012) 0.87
A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto's thyroiditis susceptibility. J Clin Endocrinol Metab (2014) 0.86
Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev (2011) 0.86
Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Lett (2010) 0.86
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer (2009) 0.86
Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res (2016) 0.86
Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? Int J Surg Pathol (2014) 0.86
Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas. J Endocrinol (2007) 0.85
Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol (2005) 0.85
Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. Microsc Res Tech (2003) 0.85
Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol (Oxf) (2006) 0.85
Cancer: Small papillary thyroid cancers--is BRAF of prognostic value? Nat Rev Endocrinol (2011) 0.85
RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology (2012) 0.85
Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later. J Clin Endocrinol Metab (2013) 0.84
A stem cell role for thyroid solid cell nests. Hum Pathol (2005) 0.84
Small-cell (basaloid) thyroid carcinoma: a neoplasm with a solid cell nest histogenesis? Int J Surg Pathol (2011) 0.83
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract (2002) 0.83
Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Fam Cancer (2007) 0.83
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol (2006) 0.83